Interactive Transcript
0:01
The following patient is a 52-year-old gentleman
0:03
with liver masses, otherwise healthy.
0:07
No past medical history that we know of, and we're
0:09
performing an MRI to evaluate these lesions.
0:12
So let's start looking at
0:13
some of these images here.
0:14
We'll start off with our T2-weighted images,
0:16
and as we scroll through it, we can see that there
0:18
are numerous liver lesions seen in this patient.
0:22
You can see one over here, one over
0:25
here, one over here, one over here.
0:27
And so, certainly, numerous lesions.
0:31
Predominantly in the right hepatic lobe,
0:33
there's some in the left hepatic lobe.
0:35
And if I just give you a representative
0:37
lesion here, on our T2-weighted sequence,
0:40
we can see that they're fairly hyper-
0:42
intense in their imaging appearance.
0:45
In and out of phase, I won't show, but
0:47
I'll tell you that the liver is steatotic,
0:49
but the lesions themselves are not.
0:51
Remember, again, that the liver itself
0:53
does not particularly have any features
0:55
to suggest that there is cirrhosis, and
0:57
we have no past medical history to suggest
0:59
the patient has chronic liver disease.
1:01
So I'll move on to the post-contrast
1:03
images to see what these lesions look like.
1:05
So here we have the post-contrast images,
1:07
and I'll just start scrolling through some
1:08
of these lesions, and all of them essentially
1:11
have a very, very similar imaging appearance.
1:14
I'm just going to focus on this
1:15
lesion here on the right hepatic lobe.
1:17
So here we have a T1, FATSAT, post-contrast
1:21
arterial phase, this is the portal venous phase.
1:25
And if we look at this lesion, a little
1:26
bit of motion on this exam, but we can
1:27
still see that there's a lesion over here.
1:30
It demonstrates non-RIM arterial
1:33
phase hyperenhancement.
1:35
So, we've heard that sort of phrase many
1:38
times before with respect to describing
1:40
HCCs or hepatocellular carcinomas.
1:43
I would imagine this is probably
1:45
around two centimeters in size or so.
1:48
When we look at the characteristics on the
1:49
portal venous phase, this has washout, this has
1:53
a pseudocapsule, and we see multiple lesions.
1:56
And so, when you see something like this,
1:58
there may be the temptation to call this
2:00
multifocal hepatocellular carcinoma.
2:03
And I've certainly made
2:04
that mistake in the past.
2:06
But what's important to understand is
2:08
that, again, the patient has no history
2:10
of cirrhosis, no risk factors of chronic
2:13
liver disease, and the likelihood of this
2:16
being multifocal HCC in a patient without
2:18
those risk factors is pretty small.
2:21
More likely, this is going to be
2:23
something that is spread to the liver, i.e.
2:26
metastatic disease, and certainly there's some
2:27
metastatic disease that give you hypervascular
2:30
metastases that can look quite similar to
2:34
what a hepatocellular carcinoma can look like.
2:36
But they're not gonna be HCCs.
2:39
They're gonna be hypervascular metastases.
2:41
And the common tumors that do that, they
2:44
need to think about are neuroendocrine
2:46
tumors, renal cell carcinomas, melanoma,
2:49
thyroid carcinomas, and there's a whole
2:54
laundry list of them, but these are some
2:56
of the more common ones that can do it.
2:57
So again, the teaching point here
3:00
is that hypervascular METs can look
3:01
like hepatocellular carcinomas.
3:04
You're going to see multiple lesions in
3:07
patients who do not have cirrhosis or
3:09
don't have any history of chronic liver
3:13
disease or any risk factors to place
3:15
them at risk for chronic liver disease.
3:17
So if you see lesions like this, you've
3:19
got to think of hypervascular METs.
3:21
You've got to look around the
3:22
body to see if there's anything
3:24
primary relating from some
3:25
of these primary tumors.
3:26
And ultimately, you'd have to
3:28
biopsy it to make the diagnosis.
© 2024 Medality. All Rights Reserved.